Business Context and Reporting Period
This Form 8-K Current Report was filed by Gossamer Bio, Inc. on November 28, 2023. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of John Quisel, J.D., Ph.D., as a Class III director, effective November 28, 2023. His initial term expires at the 2024 annual meeting of stockholders. Additionally, Dr. Quisel was appointed to the Audit Committee. The Board has determined that Dr. Quisel qualifies as an independent director under Nasdaq Global Select Market listing requirements.
Management Commentary and Compensation
Dr. Quisel's appointment was recommended by the Nominating and Corporate Governance Committee. His background includes serving as President and CEO of Disc Medicine, Inc. since 2020, and previously holding various roles at Acceleron Pharma Inc., most recently as Chief Business Officer.
Compensatory arrangements for Dr. Quisel include:
- An annual cash retainer of $40,000 for Board service.
- An annual cash retainer of $7,500 for Audit Committee service.
- An option to purchase 230,000 shares of common stock, granted on the date of appointment, vesting monthly over three years.
Dr. Quisel has also entered into the Company's standard Indemnification Agreement. No other arrangements or understandings regarding his appointment were disclosed.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 230,000 stock options granted to Dr. Quisel.
- Confirm Dr. Quisel's independence status and any potential conflicts of interest given his role at Disc Medicine, Inc.
- Review the attached Press Release (Exhibit 99.1) for additional context on the strategic rationale for this appointment.
- Check subsequent filings for any changes to the Board composition or Audit Committee membership.